Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Spivack, Phyllis (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07998967
ABSTRACT:
Methods are provided for using methotrexate (MTX) in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of MTX in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
REFERENCES:
patent: 5736531 (1998-04-01), von Borstel et al.
patent: 5968914 (1999-10-01), von Borstel et al.
patent: 6066668 (2000-05-01), Hausheer et al.
patent: 6344447 (2002-02-01), von Borstel et al.
patent: 6992072 (2006-01-01), Walker
patent: 7166581 (2007-01-01), von Borstel et al.
Stella (Expert Opinion on Therapeutic Patents, Prodrugs as therapeutics, vol. 14, No. 3, pp. 277-280; 2004).
Wolff (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977; 1994).
Testa (Biochemical Pharmacology, Prodrug Research: futile or fertile?, vol. 68, pp. 2097-2106; 2004).
Ettmayer et al. (Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, vol. 47, No. 10, pp. 2394-2404; 2004).
Morissette et al. (Advanced Drug Delivery Reviews, vol. 56, pp. 275-300; 2004).
Vippagunta et al. (Advanced Drug Delivery Reviews, vol. 48, Abstract; 2001).
Ashour et al., “5-(m-Benzyloxynezyl) barbituric Acid Acyclonucleoside, a Uridine Phosphorylase Inhibitor, and 2′, 3′, 5′—Tri-0-Acetyluridine, a Prodrug of Uridine, as Modulators of Plasma Uridine Concentration”; Biochemical Pharmacology; vol. 51, pp. 1601-1611 (1996).
Ashour et al., “Effect of 5-(phenylselenenyl) acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′, 3′, 4′—tri-0-acetyluridine, a prodrug of uridine: releavance to uridine rescue in chemotherapy”; Cancer Chemo. Pharmacol. (2000): 46:235-240.
Ashour et al., “Modulation of 5-Fluorouracil Host Toxicity by 5-(Benzyloxynezyl) barbituric Acid Acyclonucleoside, a Uridine Phosphorylase Inhibitor, and 2′, 3′, 5′—Tri-0-Acetyluridine, a Prodrug of Uridine”; Biochemical Pharmacol. vol. 60, pp. 427-431 (2000).
Brunetti et al., “5-Fluorouracil Enhances Azidothymidine Cytotoxicity: In Vitro, in Vivo, and Biochemical Studies”; Cancer Research 50: 4026-4031 (1990).
Christensen et al., “Effect of Hydration and Methotrexate Plasma Concentrations in Children With Acute Lymphocytic Leukemia”; J. Clin Oncology 6:797-801 (1988).
Darnowski et al., “Fluorouracil plus azidothynidine cytotoxicity in vitro: Relationship to cellular thymidine kinase activity”; Proc. of American Assoc. for Cancer Research; vol. 31: 398 (1990).
Darnowski et al., “Resistance to Azido-Thymidine Cytotoxicity in the Human Colon Tumor Cell Line HCT15 is Associated with Enhanced Removal of AZT from Cellular DNA”; Proc. of American Assoc. for Cancer Research; vol. 32: 358 (1991).
Drabikowska et al., “Inhibitor Properties of Some 5-Substituted Uracil Acyclonucleosides, and 2,2′—Anhydrouridines Versus Uridine Phosphorylase FromE. coliand Mammalian Sources”; Biochemical Pharmacology, vol. 36, No. 23: 4125-4128 (1987).
Howell et al., “Thymidine Rescue of High-Dose Methotrexate in Humans”, Cancer Research 38:325-330 (1978).
Howell et al., “Cytokinetic Comparison of Thymidine and Leucovorin Rescue of Marrow in Humans after Exposure to High-Dose Methotrexate”; Cancer Research 39: 1315-1320 (1979).
Iigo et al., “Differential Effects of 2,2′-Anhydro-5-Ethyluridine, A Uridine Phosphorylase Inhibitor, On the Antitumor Activity of 5-Fluorouridine and 5-Fluoro-2′-Deoxyuridine”; Biochemical Pharmacol. vol. 39, No. 7: 1247-1253 (1990).
Martin et al., “High-Dose 5-Fluorouracil with Delayed Uridine ‘Rescue’ in Mice”; Cancer Research 42: 3964-3970 (1982).
Martin et al., “Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine”; Cancer Cemotherapy Pharmacol. 24: 9-14 (1989).
Newman et al., “Increased Sensitivity to Azidothymidine in a Subline of CCRF-CEM Human Leukemia Cells Resistant to Methotrexate”; Proceedings of the American Assoc. for Cancer Research vol. 32: 413 (1991).
Pizzorno et al., “Phase I Clinical and Pharmacological Studies of Benzylacyclouridine, a Uridine Phosphorylase Inhibitor”; Clinical Cancer Research vol. 4: 1165-1175 (1998).
Scanlon et al., “Overexpression of DNA Replication and Repair Enzymes in Cisplatin-Resistant Human Colon Carcinoma HCT8 Cells and Circumvention by Azidothymidine”; Cancer Communications vol. 1, No. 4: 269-275 (1989).
Semon et al., “Potentiation of the Antitumor Activity of Methotrexate by Concurrent Infusion of Thymidine”; Cancer Research 38: 2905-2911 (1978).
Sterba et al., “High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?”; Neoplasma 52: 6 (2005) 456-463.
Tattersall et al., “The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects”; Nature 17:253 (5488): 198 (1975).
Tosi et al., “Azidothymidine-induced Cytotoxicity and Incorporation into DNA in the Human Colon Tumor Cell Line HCT-8 is Enhanced by Methotrexate in Vitro and in Vivo”; Cancer Research 52; 4069-4073 (1992).
Veres et al., “Inhibition of uridine phosphorylase by pyrimidine nucleoside analogs and consideration of substrate binding to the enzyme based on solution conformation as seen by NMR spectroscopy”; Eur. J. Biochem. 178: 173-181 (1988).
Weber et al., “Azidothymidine Inhibition of Thymidine Kinase and Synergistic Cytotoxicity with MethoTrexate and 5-Fluorouracil in Rat Hepatoma and Human Colon Cancer Cells”; Cancer Communications vol. 2: 129-133 (1990).
Weber et al., “AZT: A Biochemical Response Modifier of Methotrexate and 5-Fluorouracil Cytotoxicity in Human Ovarian and Pancreatic Carcinoma Cells”; Cancer Communications vol. 3, No. 4: 127-132 (1991).
Weber et al., “Regulation of De Novo and Salvage Pathways in Chemotherapy”; Adv. Enzyme Regul. 31: 45-67 (1991).
Frenzel Brian D.
Garland William A.
Karg Travis
Blakely, III Nelson
Bozicevic Field & Francis LLP
Field Bret E.
Foulds Glenn J.
Spivack Phyllis
LandOfFree
Methotrexate adjuvants to reduce toxicity and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methotrexate adjuvants to reduce toxicity and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methotrexate adjuvants to reduce toxicity and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2753005